COVID-19 Info: 

We are scheduling vaccinations for those who are eligible. Learn more:

 

COVID-19 Treatments and Therapeutics

UW Medicine offers the following COVID-19 therapeutics for patients with an active COVID-19 infection:

  • Sotrovimab monoclonal antibody infusion therapy. Learn more.
  • Paxlovid oral antiviral medication. Learn more.

UW Medicine also offers Evusheld monoclonal antibody therapy for pre-exposure prevention. Learn more.

Supply is very limited, and all these treatments are only available by going through an approval process for an appointment or prescription. Please DO NOT go to the emergency department or pharmacy to request monoclonal antibody therapy or oral antivirals.

How to request COVID-19 therapy for an active COVID-19 infection

Patients must be screened to ensure they meet the state defined eligibility criteria in order to receive treatment or oral antivirals. Monoclonal antibody infusion therapy is only given by APPOINTMENTS SCHEDULED by the UW Medicine COVID-19 Therapeutics Team and oral antivirals are only given by PRESCRIPTIONS from the UW Medicine COVID-19 Therapeutics Team.

Paxlovid may not be an appropriate therapy for all patients due to interactions with medications the patient is taking for other reasons (for example patients who have received an organ transplant are not eligible for this therapy).

Please do not go to the emergency department or pharmacy to request monoclonal antibody treatment or oral antivirals. Instead work with your primary care physician to request a referral for treatment. If you do not have a provider, send your name, contact information, vaccination status, date of COVID-19 symptom onset, and date of COVID-19 test to uwmmab@uw.edu or call 855.520.7539. The COVID-19 therapeutics team will respond to your request within 24 hours. We may direct you to see one of our providers via telemedicine.

We are using strict eligibility standards that align with NIH tier 1, and as staffing and supply allow, we may also include tier 2. 

Research treatment alternatives

Certain people, both vaccinated and unvaccinated, who are considered at higher risk of COVID-19 complications, who are within 7 days of a positive COVID test and the start of symptoms, could be eligible to participate in COVID-19 treatment research with UW Medicine. 

All participants in the ACTIV-2 study receive either Casirivimab/Imdevimab or a newer product under study as an alternative to receiving monoclonal antibodies under the emergency use authorization (EUA).  Providers or patients can contact the UW ACTIV-2 RISE ABOVE COVID team at 206.773.7129 (7 days a week, accepting English and Spanish speakers) or refer to RiseAboveCovid to learn more. 

How to request Evusheld monoclonal antibody therapy for pre-exposure prevention

UW Medicine patients and providers DO NOT need to request or refer patients for Evusheld. If you are a UW Medicine patient who meets the highest priority criteria to receive this therapy, you are automatically entered into a lottery for clinical review and the COVID-19 therapeutics team or your provider will contact you if you are selected. UW Medicine cares for thousands of patients who are eligible to receive this therapy, so your patience and understanding is appreciated as we work to equitably distribute this therapy to our most vulnerable patients.

If you are not a UW Medicine patient, work with your primary care physician to request a referral for treatment. Patients must be screened to ensure they meet the state defined eligibility criteria in order to receive treatment. This treatment is not for patients with an active COVID-19 infection or for patients who have been recently exposed to COVID-19. Evusheld is given by SCHEDULED APPOINTMENTS ONLY; please DO NOT go to the emergency department to request Evusheld.